Review of TA160, 161 and 204; Technologies for the primary and secondary prevention of osteoporotic fractures¹ 

Proposal to update the guidance

The review of the above guidance was deferred in August 2012.

The Institute has now carried out a search for information relevant to this appraisal, and commissioned an additional piece of analysis from the Decision Support Unit (DSU).  Following this we believe that it is appropriate for the guidance to be updated.

In order to be completely confident that this is appropriate, we are asking   consultees and commentators with an interest in this topic, to inform us of any evidence which would suggest that a review would be beneficial.  We would particularly like to be made aware of timelines around on-going research, etc. which might affect the scheduling of this review should we go ahead with the proposal following this consultation. Please see appendix A for a full list of the organisations we have contacted.

August 2013

Proposals for ¹ Review of TA160; Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women, TA161; Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, and TA204; Denosumab for the prevention of osteoporotic fractures in postmenopausal women.